JP2015227351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015227351A5 JP2015227351A5 JP2015140309A JP2015140309A JP2015227351A5 JP 2015227351 A5 JP2015227351 A5 JP 2015227351A5 JP 2015140309 A JP2015140309 A JP 2015140309A JP 2015140309 A JP2015140309 A JP 2015140309A JP 2015227351 A5 JP2015227351 A5 JP 2015227351A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antimetabolite
- cancer
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000000340 anti-metabolite Effects 0.000 claims 3
- 239000002256 antimetabolite Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- CGXLVFZJJOXEDF-UHFFFAOYSA-N 1,8-naphthyridine-3-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CN=C21 CGXLVFZJJOXEDF-UHFFFAOYSA-N 0.000 claims 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000259 anti-tumor Effects 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55357804P | 2004-03-15 | 2004-03-15 | |
US60/553,578 | 2004-03-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014091125A Division JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Sns−595、及びその使用方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016248041A Division JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Sns−595、及びその使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015227351A JP2015227351A (ja) | 2015-12-17 |
JP2015227351A5 true JP2015227351A5 (US20070167479A1-20070719-C00034.png) | 2016-02-04 |
JP6352863B2 JP6352863B2 (ja) | 2018-07-04 |
Family
ID=34993432
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Sns−595、及びその使用方法 |
JP2012036919A Pending JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Sns−595、及びその使用方法 |
JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Sns−595、及びその使用方法 |
JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Sns−595、及びその使用方法 |
JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Sns−595、及びその使用方法 |
JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Sns−595、及びその使用方法 |
JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Sns−595、及びその使用方法 |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Sns−595、及びその使用方法 |
JP2012036919A Pending JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Sns−595、及びその使用方法 |
JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Sns−595、及びその使用方法 |
JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Sns−595、及びその使用方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Sns−595、及びその使用方法 |
JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Sns−595、及びその使用方法 |
Country Status (24)
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06010382A (es) * | 2004-03-15 | 2007-04-23 | Sunesis Pharmaceuticals Inc | Sns-595 y metodos para utilizar el mismo. |
US7816406B2 (en) | 2004-09-17 | 2010-10-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs |
US7652134B2 (en) | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
US20070117770A1 (en) * | 2005-08-19 | 2007-05-24 | Cylene Pharmaceuticals, Inc. | Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof |
CA2620915C (en) * | 2005-09-02 | 2014-03-25 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
WO2007028171A1 (en) * | 2005-09-02 | 2007-03-08 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
CA2654876A1 (en) | 2006-06-12 | 2007-12-21 | Sunesis Pharmaceuticals, Inc. | 1-8-naphthyridine compounds for the treatment of cancer |
WO2008016678A2 (en) * | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
EP3025712A1 (en) * | 2006-08-02 | 2016-06-01 | Sunesis Pharmaceuticals, Inc. | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia |
AU2008310883A1 (en) * | 2007-10-09 | 2009-04-16 | Hamann, Mark T | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter |
CA2703044C (en) * | 2007-10-22 | 2016-05-10 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
AU2014277779B2 (en) * | 2007-10-22 | 2016-05-19 | Sunesis Pharmaceuticals, Inc. | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY |
AU2008335772B2 (en) * | 2007-12-10 | 2014-11-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
NZ593763A (en) | 2008-12-31 | 2013-11-29 | Sunesis Pharmaceuticals Inc | Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
AU2010217796B2 (en) | 2009-02-27 | 2015-04-30 | Sunesis Pharmaceuticals, Inc. | Methods of using SNS-595 for treatment of cancer subjects with reduced BRCA2 activity |
UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
WO2011056566A2 (en) * | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
CN104244697B (zh) | 2012-02-27 | 2018-04-27 | 阿吉齐科技公司 | 土壤条件的监测与控制 |
SI2841428T1 (sl) | 2012-04-24 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
WO2014169067A1 (en) * | 2013-04-09 | 2014-10-16 | Merrimack Pharmaceuticals, Inc. | Compositions for improving outcomes of liposomal chemotherapy |
WO2015000034A1 (en) * | 2013-07-02 | 2015-01-08 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iii |
EP3424920B1 (en) | 2013-10-17 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
KR101775356B1 (ko) * | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
AU2017335648B2 (en) | 2016-09-27 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US216316A (en) * | 1879-06-10 | Improvement in latches | ||
US3021A (en) * | 1843-03-30 | Stove with elevated ovejst | ||
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
NZ287139A (en) * | 1994-06-14 | 1997-07-27 | Dainippon Pharmaceutical Co | Naphthyridine derivatives; preparative process and anti-tumour medicaments |
JP4323574B2 (ja) | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
WO1998030902A1 (en) * | 1997-01-13 | 1998-07-16 | Kudos Pharmaceuticals Limited | Assays, agents, therapy and diagnosis relating to modulation of cellular dna repair activity |
US20020032216A1 (en) * | 1997-03-21 | 2002-03-14 | Lg Chemical Ltd. | Salt of naphthyridine carboxylic acid derivative |
CA2293724C (en) | 1997-06-05 | 2010-02-02 | Xiaodong Wang | Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
US6171857B1 (en) * | 1997-10-17 | 2001-01-09 | Brown University Research Foundatiion | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity |
US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
IL124015A0 (en) * | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
JP4294121B2 (ja) | 1998-06-05 | 2009-07-08 | 大日本住友製薬株式会社 | ピリドンカルボン酸誘導体の製造方法およびその中間体 |
ATE362994T1 (de) * | 1998-06-30 | 2007-06-15 | Sloan Kettering Inst Cancer | Verwendung von dna-pk |
EP1161444A4 (en) | 1999-02-26 | 2005-11-02 | Univ Johns Hopkins | NEW INHIBITOR OF PROGRAMMED CELL DEATH |
US6670144B1 (en) * | 1999-02-26 | 2003-12-30 | Cyclacel, Ltd. | Compositions and methods for monitoring the phosphorylation of natural binding partners |
US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
EP1283903A1 (en) * | 2000-05-20 | 2003-02-19 | Cancer Research Technology Limited | Drug screening systems and assays |
AU2001288432A1 (en) * | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
WO2002036171A1 (en) * | 2000-11-02 | 2002-05-10 | Sloan Kettering Institute For Cancer Research | Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
US20050158724A1 (en) * | 2002-04-05 | 2005-07-21 | Fishel Richard A. | Methods, of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
AU2004223866A1 (en) * | 2003-03-24 | 2004-10-07 | Luitpold Pharmaceuticals, Inc. | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors |
MXPA06010382A (es) | 2004-03-15 | 2007-04-23 | Sunesis Pharmaceuticals Inc | Sns-595 y metodos para utilizar el mismo. |
WO2007028171A1 (en) | 2005-09-02 | 2007-03-08 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
CA2654876A1 (en) | 2006-06-12 | 2007-12-21 | Sunesis Pharmaceuticals, Inc. | 1-8-naphthyridine compounds for the treatment of cancer |
WO2008016678A2 (en) | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
EP3025712A1 (en) | 2006-08-02 | 2016-06-01 | Sunesis Pharmaceuticals, Inc. | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia |
CA2703044C (en) | 2007-10-22 | 2016-05-10 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
AU2008335772B2 (en) | 2007-12-10 | 2014-11-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
NZ593763A (en) | 2008-12-31 | 2013-11-29 | Sunesis Pharmaceuticals Inc | Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
AU2010217796B2 (en) | 2009-02-27 | 2015-04-30 | Sunesis Pharmaceuticals, Inc. | Methods of using SNS-595 for treatment of cancer subjects with reduced BRCA2 activity |
CN101631081B (zh) | 2009-08-12 | 2011-06-08 | 华为技术有限公司 | 一种多级交换网 |
UA110465C2 (en) * | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
WO2011056566A2 (en) | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
-
2005
- 2005-03-14 MX MXPA06010382A patent/MXPA06010382A/es active IP Right Grant
- 2005-03-14 CN CN200910221540A patent/CN101703508A/zh active Pending
- 2005-03-14 CN CN201210307785.8A patent/CN103251589B/zh not_active Expired - Fee Related
- 2005-03-14 DK DK05732554.0T patent/DK1729770T3/da active
- 2005-03-14 CA CA2559652A patent/CA2559652C/en not_active Expired - Fee Related
- 2005-03-14 WO PCT/US2005/008346 patent/WO2005089757A1/en active Application Filing
- 2005-03-14 EP EP15202939.3A patent/EP3053579A1/en not_active Withdrawn
- 2005-03-14 PL PL10177951T patent/PL2295056T3/pl unknown
- 2005-03-14 SI SI200530890T patent/SI1729770T1/sl unknown
- 2005-03-14 US US11/080,283 patent/US7989468B2/en not_active Expired - Fee Related
- 2005-03-14 MX MX2011011851A patent/MX349188B/es unknown
- 2005-03-14 DE DE602005025738T patent/DE602005025738D1/de active Active
- 2005-03-14 AT AT05732554T patent/ATE451924T1/de active
- 2005-03-14 AT AT05731600T patent/ATE493982T1/de active
- 2005-03-14 SI SI200531244T patent/SI1725233T1/sl unknown
- 2005-03-14 CN CN200580015456.4A patent/CN1997368B/zh not_active Expired - Fee Related
- 2005-03-14 JP JP2007503987A patent/JP5317472B2/ja not_active Expired - Fee Related
- 2005-03-14 DK DK10177951.0T patent/DK2295056T5/en active
- 2005-03-14 ES ES10177951.0T patent/ES2566973T3/es active Active
- 2005-03-14 EP EP05732554A patent/EP1729770B1/en not_active Not-in-force
- 2005-03-14 PT PT05731600T patent/PT1725233E/pt unknown
- 2005-03-14 PT PT05732554T patent/PT1729770E/pt unknown
- 2005-03-14 NZ NZ549557A patent/NZ549557A/en not_active IP Right Cessation
- 2005-03-14 WO PCT/US2005/008036 patent/WO2005089756A1/en active Application Filing
- 2005-03-14 PL PL05732554T patent/PL1729770T3/pl unknown
- 2005-03-14 US US11/080,102 patent/US7968565B2/en not_active Expired - Fee Related
- 2005-03-14 PL PL05731600T patent/PL1725233T3/pl unknown
- 2005-03-14 JP JP2007503972A patent/JP5096913B2/ja not_active Expired - Fee Related
- 2005-03-14 HU HUE10177951A patent/HUE027266T2/en unknown
- 2005-03-14 DK DK05731600.2T patent/DK1725233T3/da active
- 2005-03-14 DE DE602005018333T patent/DE602005018333D1/de active Active
- 2005-03-14 AU AU2005222607A patent/AU2005222607B2/en not_active Ceased
- 2005-03-14 CA CA2954578A patent/CA2954578A1/en not_active Abandoned
- 2005-03-14 ES ES05732554T patent/ES2334802T3/es active Active
- 2005-03-14 CN CN201210307920.9A patent/CN103083316B/zh not_active Expired - Fee Related
- 2005-03-14 KR KR1020067021270A patent/KR101169825B1/ko active IP Right Grant
- 2005-03-14 AU AU2005222622A patent/AU2005222622B2/en not_active Ceased
- 2005-03-14 ES ES05731600T patent/ES2358267T3/es active Active
- 2005-03-14 EP EP05731600A patent/EP1725233B1/en not_active Not-in-force
- 2005-03-14 ZA ZA200607248A patent/ZA200607248B/xx unknown
- 2005-03-14 CN CN201410477839.4A patent/CN104324029A/zh active Pending
- 2005-03-14 BR BRPI0508700-7A patent/BRPI0508700A/pt not_active IP Right Cessation
- 2005-03-14 CA CA2559650A patent/CA2559650C/en not_active Expired - Fee Related
- 2005-03-14 EP EP10177951.0A patent/EP2295056B9/en not_active Not-in-force
- 2005-04-14 NZ NZ588060A patent/NZ588060A/en not_active IP Right Cessation
- 2005-09-02 US US11/218,387 patent/US20060025437A1/en active Pending
- 2005-09-02 US US11/218,653 patent/US20060063795A1/en active Pending
-
2006
- 2006-06-29 US US11/478,765 patent/US7829577B2/en not_active Expired - Fee Related
- 2006-09-07 IL IL177946A patent/IL177946A/en not_active IP Right Cessation
- 2006-10-12 NO NO20064647A patent/NO338058B1/no not_active IP Right Cessation
-
2007
- 2007-05-07 HK HK07104836.3A patent/HK1097196A1/xx not_active IP Right Cessation
-
2010
- 2010-01-21 CY CY20101100063T patent/CY1109741T1/el unknown
-
2011
- 2011-02-03 CY CY20111100114T patent/CY1111263T1/el unknown
- 2011-03-22 AU AU2011201277A patent/AU2011201277B2/en not_active Ceased
- 2011-04-27 US US13/095,111 patent/US20110263524A1/en not_active Abandoned
- 2011-06-13 US US13/159,258 patent/US8669270B2/en not_active Expired - Fee Related
- 2011-06-17 JP JP2011135675A patent/JP2011225590A/ja active Pending
-
2012
- 2012-02-23 JP JP2012036919A patent/JP2012140442A/ja active Pending
-
2013
- 2013-03-11 US US13/794,583 patent/US8822493B2/en not_active Expired - Fee Related
-
2014
- 2014-02-03 US US14/171,673 patent/US20140378505A1/en not_active Abandoned
- 2014-04-25 JP JP2014091125A patent/JP5856644B2/ja not_active Expired - Fee Related
- 2014-08-18 US US14/462,439 patent/US9980949B2/en not_active Expired - Fee Related
- 2014-09-05 JP JP2014180862A patent/JP6261477B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-17 NO NO20150466A patent/NO339613B1/no not_active IP Right Cessation
- 2015-07-14 JP JP2015140309A patent/JP6352863B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-14 US US14/996,025 patent/US9757363B2/en not_active Expired - Fee Related
- 2016-09-26 IL IL248049A patent/IL248049A0/en unknown
- 2016-11-24 NO NO20161867A patent/NO20161867A1/no not_active Application Discontinuation
- 2016-12-21 JP JP2016248041A patent/JP2017095471A/ja active Pending
-
2018
- 2018-03-05 JP JP2018038834A patent/JP2018119977A/ja active Pending
- 2018-04-27 US US15/965,741 patent/US20180316309A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015227351A5 (US20070167479A1-20070719-C00034.png) | ||
JP2014148535A5 (US20070167479A1-20070719-C00034.png) | ||
MX2020007485A (es) | Compuestos antiproliferativos y metodos de uso de los mismos. | |
JP2016508134A5 (US20070167479A1-20070719-C00034.png) | ||
WO2016161342A3 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
EA201890458A1 (ru) | Композиции с усилителями проницаемости для доставки лекарств | |
GEP20186838B (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors | |
JP2016539157A5 (US20070167479A1-20070719-C00034.png) | ||
CY1119309T1 (el) | Συνδυασμενη χρηση toy (+)-1,4-διϋδρο-7-[(3s,4s)-3-meθoξy-4-(μεθυλαμινο)-1-πυρρολιδινυλ]-4-οξο-1(2-θειαζολυλ)-1,8-ναφθυριδιν-3-καρβοξυλικου οξεος και της κυταραβινης (ara-c) για την αγωγη της λευχαιμιας | |
JP2013526525A5 (US20070167479A1-20070719-C00034.png) | ||
NZ718708A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MX2012015279A (es) | Derivado de tetrahidrocarbonila. | |
WO2016207090A3 (en) | Targeted conjugates of ksp inhibitors | |
JP2009539994A5 (US20070167479A1-20070719-C00034.png) | ||
WO2014145443A3 (en) | Liquids rich in noble gas and methods of their preparation and use | |
GEP20207172B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
EA032938B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
WO2019244066A3 (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
JP2015502926A5 (US20070167479A1-20070719-C00034.png) | ||
WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
PH12018502735A1 (en) | Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
JP2011500805A5 (US20070167479A1-20070719-C00034.png) | ||
WO2015193517A3 (en) | Liquid pharmaceutical composition comprising pemetrexed |